Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


 

Krka Sets Out Strategy In Multiple Markets

Krka has revealed its new growth strategy for 2020-2024, including growing through joint ventures, partnerships and acquisitions and focusing on European, central Asian and Chinese markets. At the same time, the Slovenian firm has reported that its sales jumped by 12% in the first nine months of 2019.

Business Strategies Strategy

Consensus Is Essential To Find Best Value-Added Path

Finding a consensus across European stakeholders on how best to recognize and reward the benefits of value added medicines is key to the sector’s success, says Arun Narayan – chairman of the value added medicines sector group at Medicines for Europe and also head of global portfolio strategy and head of European business operations at Mylan – in an exclusive interview with Generics Bulletin.

Value-Added Medicines Regulation Europe

US Trastuzumab Competition Heats Up

Mylan and Biocon have launched their Ogivri trastuzumab biosimilar in the US, marking the second biosimilar rival to Herceptin and leading a new wave of trastuzumab biosimilars expected to arrive in the US early next year.

Biosimilars Launches United States

A Patient-centric Approach to Digital Value Added Medicines

Registration is open for our new webinar, Wednesday, October 30, 2019, 10:00 AM Eastern Daylight Time. Value added medicines are therapies where innovation has been applied around an off-patent molecule, for example by reformulation or applying a device. It is an emerging sector that promises to serve the needs of patients who struggle to take their medicines as prescribed.

REGISTER NOW!

Embedding Time-Critical Scheduling in Drug Production

Manufacturing is the engine room of the pharmaceutical industry. Ultimately, a medicine has little value if it does not reach patients on schedule, in the required quantity and quality. Download this whitepaper which discusses time-critical scheduling in drug production.

Download Whitepaper
 

Commercial Explore this Topic

Krka Sets Out Strategy In Multiple Markets

Krka has revealed its new growth strategy for 2020-2024, including growing through joint ventures, partnerships and acquisitions and focusing on European, central Asian and Chinese markets. At the same time, the Slovenian firm has reported that its sales jumped by 12% in the first nine months of 2019.

Business Strategies Strategy

Cadila Healthcare Merges Four Subsidiaries

India’s Cadila Healthcare, which has been suffering on the earnings front, is amalgamating four subsidiaries under its roof to reduce overheads from managing separate entities and avoid duplication of efforts after posting weak second-quarter earnings.

Business Strategies Strategy

Egypt’s Rameda Prices Public Offering

Through an initial public offering, Egyptian branded generics supplier Rameda intends to raise funds to buy both products and companies in the Middle East and North Africa.


Business Strategies Middle East and Africa

Ophthalmics Are Next Frontier For Teligent

US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.

 

Ophthalmic Business Strategies

Piramal Looks To Build On Pharma Growth

Piramal says it is looking to build on the 17% growth in its Global Pharma business reported in its financial second quarter by investing in manufacturing expansion across differentiated product areas.

Strategy Sales & Earnings

Cipla's COO Steps Down

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

Leadership Strategy
See All

Policy & Regulation Explore this Topic

Rising's Generic Price Fixing Settlement Follows Bankruptcy, Cooperation

Rising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.
Generic Drugs Legal Issues

IPA Honors DG Shah With Public-Policy Award

In honor of its former secretary-general DG Shah, the Indian Pharmaceutical Alliance has created a public policy award at the Indian Institute of Management in Ahmedabad.

India Policy

EU Report Puts Generics And Biosimilars In The Frame

EU member states are being urged by the European Commission to cooperate more closely on pricing and reimbursement, managed access deals and policies to promote generics and biosimilars.

Europe Regulation

Missed ANDA Nods Mostly Due To 'Imminent Approval'

US FDA will miss goal dates to reach speedier generic drug application approvals, but says decisions will be case by case.

Regulation Review Pathway

Biocon And Mylan Prime Pegfilgrastim Expansion

Biocon-Mylan’s sBLA for pegfilgrastim made at a new Indian site gets an FDA go-ahead, facilitating a "multi-fold" scale up in capacity. But it will be interesting to watch how impactful this could be on market dynamics in the US, where more competition has arrived.

Regulation Biosimilars

European Industry Seeks Action On Shortages

Medicines For Europe has called on EU leaders to take action on the issue of medicine shortages, urging the new European Commission to prioritize shortage prevention in its first 100 days.

Regulation Europe
See All

Generic Drugs Explore this Topic

Rising's Generic Price Fixing Settlement Follows Bankruptcy, Cooperation

Rising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.
Generic Drugs Legal Issues

Sun Fights US Charges Over Delays

Sun Pharmaceutical Industries is back before US courts as it contests US antitrust charges filed by plaintiffs over the delayed market entry of generic versions of three major drugs.

Legal Issues Launches

Egypt’s Rameda Prices Public Offering

Through an initial public offering, Egyptian branded generics supplier Rameda intends to raise funds to buy both products and companies in the Middle East and North Africa.


Business Strategies Middle East and Africa
See All

Biosimilars Explore this Topic

Krka Sets Out Strategy In Multiple Markets

Krka has revealed its new growth strategy for 2020-2024, including growing through joint ventures, partnerships and acquisitions and focusing on European, central Asian and Chinese markets. At the same time, the Slovenian firm has reported that its sales jumped by 12% in the first nine months of 2019.

Business Strategies Strategy

EU Report Puts Generics And Biosimilars In The Frame

EU member states are being urged by the European Commission to cooperate more closely on pricing and reimbursement, managed access deals and policies to promote generics and biosimilars.

Europe Regulation

Kamada Licenses Alvotech Biosimilars In Israel

Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.

Deals Biosimilars
See All

Value-Added Medicines Explore this Topic

Advanz Sees Mumbai Center As Strategic Strength

Using its Indian back-office function to realize synergies from acquired sales and marketing assets in western Europe forms a key part of Advanz Pharma’s growth strategy.

Business Strategies M & A

Rovi Is Weeks From Long-Acting Risperidone Filing

Rovi hopes by the end of this year to file a hybrid marketing authorization application in Europe for a once-a-month sustained-release injectable formulation of risperidone. A US filing is scheduled for the first half of next year.

Value-Added Medicines Neurology

European Industry Sets Out Value Added Medicines Priorities

Incentives for innovation around known molecules and new guidelines for value added medicines are needed, Medicines for Europe has insisted at the organization’s value added medicines conference in Brussels yesterday. The European off-patent industry association has called for a “pragmatic value framework” to recognize value added medicines, as well as welcoming the advent of digital health solutions.

Value-Added Medicines Regulation
See All
UsernamePublicRestriction

Register